PATIENT REPORTED OUTCOMES AND IMPROVEMENTS IN INTRAVAGINAL EJACULATORY LATENCY TIME IN DAPOXETINE-TREATED MEN WITH LIFELONG OR ACQUIRED PREMATURE EJACULATION: PHASE 3 POOLED ANALYSES

Premature Ejaculation ◽

Latency Time ◽

Phase 3 ◽

Ejaculatory Latency ◽

383 PATIENT REPORTED OUTCOMES BY VARYING BASELINE INTRAVAGINAL EJACULATORY LATENCY TIME IN DAPOXETINETREATED MEN WITH PREMATURE EJACULATION: POLED ANALYSIS OF 4 PHASE 3 TRIALS

European Urology Supplements ◽

10.1016/s1569-9056(09)60385-7 ◽

2009 ◽

Vol 8 (4) ◽

pp. 216

Author(s):

F. Giuliano ◽

S. Althof ◽

J.M. Kaufman ◽

J. Buvat ◽

S. Bull ◽

...

Keyword(s):

Premature Ejaculation ◽

Latency Time ◽

Phase 3 ◽

Ejaculatory Latency ◽

Efficacy of Dapoxetine for the Treatment of Premature Ejaculation: A Meta-analysis of Randomized Clinical Trials on Intravaginal Ejaculatory Latency Time, Patient-reported Outcomes, and Adverse Events

Urology ◽

10.1016/j.urology.2015.01.009 ◽

2015 ◽

Vol 85 (4) ◽

pp. 856-861 ◽

Cited By ~ 18

Author(s):

Fa-Gui Yue ◽

Lei Dong ◽

Ting-Ting Hu ◽

Xiao-Yu Qu

Keyword(s):

Clinical Trials ◽

Adverse Events ◽

Premature Ejaculation ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Latency Time ◽

Ejaculatory Latency ◽

The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX)

Journal of Sexual Medicine ◽

10.1016/j.jsxm.2019.05.016 ◽

2019 ◽

Vol 16 (8) ◽

pp. 1178-1187 ◽

Cited By ~ 2

Author(s):

Christopher McMahon ◽

Stanley Althof ◽

Raymond Rosen ◽

Francois Giuliano ◽

Martin Miner ◽

...

Keyword(s):

Premature Ejaculation ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Ejaculatory Latency ◽

Patient Reported ◽

Oxytocin Antagonist ◽

Lifelong Premature Ejaculation

Faculty Opinions recommendation of Ejaculatory latency vs. patient-reported outcomes (PROs) as study end points in premature ejaculation clinical trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1082922.535880 ◽

2007 ◽

Author(s):

Chiara Simonelli

Keyword(s):

Clinical Trials ◽

Premature Ejaculation ◽

End Points ◽

Ejaculatory Latency ◽

Ejaculatory Latency vs. Patient-Reported Outcomes (PROs) as Study End Points in Premature Ejaculation Clinical Trials

European Urology ◽

10.1016/j.eururo.2007.03.081 ◽

2007 ◽

Vol 52 (2) ◽

pp. 321-323 ◽

Cited By ~ 11

Author(s):

Chris G. McMahon

Keyword(s):

Clinical Trials ◽

Premature Ejaculation ◽

End Points ◽

Ejaculatory Latency ◽

Prevalence and impact of premature ejaculation in outpatients complaining of ejaculating prematurely: using the instruments of intravaginal ejaculatory latency time and patient-reported outcome measures

International Journal of Impotence Research ◽

10.1038/ijir.2013.42 ◽

2014 ◽

Vol 26 (3) ◽

pp. 94-99 ◽

Cited By ~ 10

Author(s):

J Gao ◽

X Zhang ◽

P Su ◽

K Shi ◽

D Tang ◽

...

Keyword(s):

Outcome Measures ◽

Premature Ejaculation ◽

Patient Reported Outcome Measures ◽

Patient Reported Outcome ◽

Latency Time ◽

Ejaculatory Latency ◽

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.95 ◽

2017 ◽

Vol 1 ◽

pp. s96

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract Not AvailableDisclosure: Study supported by Dermira.

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.41 ◽

2018 ◽

Vol 2 ◽

pp. S41

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract not available. Disclosures: Study supported by Dermira. Copyright SKIN 2018

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.1239 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 412.2-413 ◽

Cited By ~ 1

Author(s):

E. Keystone ◽

P. Taylor ◽

Y. Tanaka ◽

C. Gaich ◽

A.M. DeLozier ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Inadequate Response ◽

Phase 3 ◽

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-019-02894-3 ◽

2019 ◽

Vol 145 (6) ◽

pp. 1589-1599 ◽

Cited By ~ 6

Author(s):

Jorge E. Cortes ◽

◽

Carlo Gambacorti-Passerini ◽

Michael W. Deininger ◽

Michael J. Mauro ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Chronic Phase ◽

Newly Diagnosed ◽

Phase 3 ◽